Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL331177 | 0.85 | RARA (0.40) | TDP1ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL17625973 | 0.84 | KDM4E (0.40) | ALDH1A1MAPTKDM4EGAASMN1; SMN2 | |
| SCHEMBL17626018 | 0.84 | ALDH1A1 (0.37) | ALDH1A1MAPTKDM4ESMN1; SMN2MAPK1 | |
| SCHEMBL17626168 | 0.84 | ALDH1A1 (0.38) | ALDH1A1GAAADORA2AADORA1HTT | |
| SCHEMBL2398650 | 0.81 | SMN1; SMN2 (0.50) | ALDH1A1MAPTGAASMN1; SMN2LMNA | |
| SCHEMBL2396548 | 0.81 | DHODH (0.38) | MAPTKDM4EHPGDSMN1; SMN2NPSR1 | |
| SCHEMBL2397319 | 0.81 | KIF11 (0.41) | TDP1ALDH1A1KDM4EHPGDKMT2A | |
| SCHEMBL17628675 | 0.80 | SMN1; SMN2 (0.35) | SMN1; SMN2 | |
| SCHEMBL1436527 | 0.80 | MKNK1 (0.42) | KDM4EMAPK1LMNAKMT2AMEN1 | |
| SCHEMBL1436026 | 0.80 | GAA (0.42) | ALDH1A1GAANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102245574-A | Compounds, pharmaceutical compositions and methods for treating metabolic disorders | EUROSCREEN SA | 2011-11-16 | — | — | CN | claimed |
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | claimed |
| EP-2364297-A1 | Compounds, pharmaceutical composition and methods for use in treating metabolic disorders | Euroscreen S.A. (BE) | 2011-09-14 | — | — | EP | claimed |
| WO-2011076734-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | claimed |
| WO-2011076732-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING GASTROINTESTINAL DISORDERS | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | claimed |
| WO-2010066682-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2010-06-17 | — | — | WO | claimed |
| CN-102245574-A | Compounds, pharmaceutical compositions and methods for treating metabolic disorders | EUROSCREEN SA | 2011-11-16 | — | — | CN | disclosed |
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | disclosed |
| EP-2364297-A1 | Compounds, pharmaceutical composition and methods for use in treating metabolic disorders | Euroscreen S.A. (BE) | 2011-09-14 | — | — | EP | disclosed |
| WO-2011076734-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076732-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING GASTROINTESTINAL DISORDERS | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2010066682-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | TDP1 4222/4885ALDH1A1 623/4885MAPT 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.